Central venous catheter placement at the time of extracorporeal membrane oxygenation decannulation: is it safe?

PURPOSE: Because of concerns for infectious and hemorrhagic complications, methods of obtaining central venous access after extracorporeal membrane oxygenation (ECMO) vary by institution. For infants requiring ECMO, it has been our practice to exchange the venous cannula for a tunneled central venous catheter (Broviac) at the time of decannulation. The purpose of this study is to compare the incidence of catheter-related complications in these patients to a national registry. METHODS: The medical records of all non-cardiac surgery infants, 12 months or younger, requiring ECMO at our institution from 1993 to 2005 (n = 138) were reviewed. Complete information was available for 134. Center for Disease Control criteria was used to identify cases of catheter-related bloodstream infections (BSIs). Data from the National Nosocomial Infections Surveillance system served as a comparative group. Logistic regression was used to determine risk factors for catheter-related BSI. RESULTS: A total of 134 infants spent a mean of 8.1 +/- 4.3 days (range, 1-21 days) on ECMO. At the time of decannulation, a Broviac catheter was placed in the right internal jugular vein of 95 (71%) and remained in place for a mean of 18.2 +/- 17 days (range, 1-109 days). The incidence of BSI related to these catheters was not significantly different than that reported by the National Nosocomial Infections Surveillance system for all central venous catheters over a similar period (6.4/1000 vs 7.3/1000 catheter days; P = .68). The number of days on ECMO and number of catheter days were independent predictors of catheter-related BSI in both bivariate and multivariate logistic regression models (P

Increasing use of extracorporeal life support in methicillin-resistant Staphylococcus aureus sepsis in children.

BACKGROUND: Pediatric cases of fulminant community-associated methicillin-resistant Staphylococcus aureus (MRSA) infections requiring extracorporeal life support (ECLS) have been reported, but the frequency of ECLS use for severe presentations of staphylococcal disease is unknown. OBJECTIVE: To describe the frequency and characteristics of children with MRSA infections requiring ECLS using local and international databases. METHODS: The reasons for use of ECLS in children 0-18 yrs of age were determined in both the Vanderbilt Children's Hospital medical record system and the Extracorporeal Life Support Organization database during the years 1994-2005. Demographic characteristics, ventilatory management, and measurements of cardiopulmonary status in subjects undergoing ECLS with a pre-ECLS diagnosis of infection with Staphylococcus aureus and MRSA were included. RESULTS: Three subjects with MRSA sepsis requiring ECLS were identified at Vanderbilt since 2000. Before that time, no cases due to MRSA were reported. The three subjects were previously healthy adolescents with severe necrotizing pneumonia associated with skin/soft-tissue infection and two died. A total of 45 patients requiring ECLS for MRSA infection were identified in the International Extracorporeal Life Support Organization database, with nearly half reported in the past 2 yrs (20 of 45 patients). The median age was 2.4 yrs (interquartile range, 0.36-14 yrs), with peaks noted in infancy and adolescence. In Extracorporeal Life Support Organization subjects with MRSA, survival to discharge was highest in infants and young children aged 1-4 yrs (65% and 71%, respectively) and lowest in the age ranges of 5-9 yrs and 13-18 yrs (0% and 31%, respectively). There were no statistically significant differences in pre-ECLS ventilatory settings, cardiopulmonary status, or frequency of complications between survivors and nonsurvivors. CONCLUSIONS: The use of ECLS for MRSA infection seems to be increasing both locally and internationally. High mortality rates, particularly in older patients, are concerning and highlight the increasing problem with this pathogen.